| 0.881 -0.009 (-1.01%) | 03-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.16  |
1-year : | 1.27 |
| Resists | First : | 1 |
Second : | 1.09 |
| Pivot price | 0.92  |
|||
| Supports | First : | 0.85 |
Second : | 0.7 |
| MAs | MA(5) : | 0.9 |
MA(20) : | 0.92 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.2 |
D(3) : | 22.6 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 1.75 | Low : | 0.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALPS ] has closed above bottom band by 25.3%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 0.93 - 0.94 | 0.94 - 0.94 |
| Low: | 0.87 - 0.87 | 0.87 - 0.88 |
| Close: | 0.87 - 0.88 | 0.88 - 0.89 |
Alps Group Inc is an integrated biotechnology platform providing research and development, medical services, and wellness solutions focused on advanced therapies. The company aims to create a fair healthcare ecosystem with accessible predictive, preventive, and precision medicine.
Tue, 24 Feb 2026
Alps Group Emerges as Nasdaq-Listed Biotech Contender - AD HOC NEWS
Mon, 23 Feb 2026
Alps Group Publishes Peer-Reviewed Data Backing Safety of Novel NK Cell Therapy Platform - TipRanks
Mon, 23 Feb 2026
New Alps Group cell therapy shows early safety in nine-patient study - Stock Titan
Sun, 08 Feb 2026
Alps Advisors Inc. Sells 36,230 Shares of Altria Group, Inc. $MO - MarketBeat
Thu, 08 Jan 2026
Alps Group appoints Cheing Lye-Ping as new CFO - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|